LUTRIS PHARMA

lutris-pharma-firma

Improving anti-cancer therapy by reducing dose-limiting side effects

Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with EGFR (Epidermal Growth Factor Receptor) inhibitors or with radiation, where dermal toxicity often leads to a reduction of anti-cancer therapy compliance. The company aims to provide novel topical therapies in order to mitigate these side effects. Lutris Pharma’s lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule currently in a phase 2 clinical trial in metastatic colorectal cancer patients with EGFR inhibitor induced acneiform lesions and a phase 1/2 study for the treatment of radiation-induced dermatitis.

CEO
Noa Shelach

WEB
LUTRIS PHARMA

INVESTED COMPANY
2025

DETAILS
Lutris Pharma
27 Habarzel Street,
Tel Aviv, IL.

News